Target intelligence / Profile preview

ATP-dependent metalloprotease YME1L1 (YME1L1)

Target
YME1L1
Molecular classification
Enzyme, ATPase, Metalloprotease, AAA family protein (ATPases Associated with diverse cellular Activities)
01

Overview

ATP-dependent metalloprotease YME1L1 is an enzyme embedded in the inner mitochondrial membrane and belongs to the AAA family of ATPases. It is crucial for the maintenance of mitochondrial morphology, mitochondrial protein quality control, and regulation of protein import and turnover within mitochondria. By degrading unfolded, misfolded, or otherwise regulatory proteins—including those involved in protein import, respiratory chain complexes, and mitochondrial dynamics—it preserves mitochondrial function and structure. YME1L1 also regulates the balance between mitochondrial fusion and fission through proteolytic processing of OPA1. Deficiency or dysfunction in YME1L1 leads to perturbations in mitochondrial dynamics, increased susceptibility to apoptosis, and contributes to disease phenotypes including infantile-onset mitochondriopathies, optic atrophy, and may play a role in certain cancers and neurodegenerative conditions[1][2][3][4][5][6][7].

Other names
YME1 like 1 ATPaseYME1L1YME1-like protein 1i-AAA protease (inner mitochondrial membrane AAA protease)YM EL1_HUMAN
02

Mechanism of action

ATP-dependent degradation of unfolded, misfolded, or regulatory mitochondrial proteins; Maintenance of mitochondrial morphology via OPA1 cleavage and turnover; Regulation of mitochondrial protein import machinery (TIM22, TIM23); Turnover of electron transport chain proteins and mitochondrial lipid biosynthetic enzymes

03

Biological functions

Regulation of mitochondrial morphologyMitochondrial protein quality control and degradationRegulation of mitochondrial dynamics (protein import, fission, fusion)Cristae morphogenesisMitochondrial protein biosynthesisProtection against apoptosisCell proliferation
04

Disease associations

Cancer (notably non-small cell lung cancer)Mitochondriopathy with infantile onsetOptic atrophy 11 (autosomal recessive isolated optic atrophy)Neurodegenerative disease (impairment in neural stem cell self-renewal)
05

Safety considerations

Loss leads to mitochondrial dysfunction, apoptosis, and cell deathDepletion can impair energy production and cell viabilityTherapeutic targeting may risk neuronal, muscular, or cardiac side effects due to mitochondrial dependence in these tissues
06

Biomarkers

Loss-of-function mutations in YME1L1 for diagnosis of optic atrophy 11Mutational screening for infantile-onset mitochondriopathyPossibly, alterations in YME1L1 protein expression in cancers and neurodevelopmental disorders

Beyond the preview

Go deeper on ATP-dependent metalloprotease YME1L1 (YME1L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent metalloprotease YME1L1 (YME1L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call